Endometrial cancer survival after breast cancer in relation to tamoxifen treatment:Pooled results from three countries by Jones, Michael E. et al.
  
 University of Groningen
Endometrial cancer survival after breast cancer in relation to tamoxifen treatment
Jones, Michael E.; van Leeuwen, Flora E.; Hoogendoorn, Wilhelmina E.; Mourits, Marian J.






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2012
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Jones, M. E., van Leeuwen, F. E., Hoogendoorn, W. E., Mourits, M. J. E., Hollema, H., van Boven, H., ...
Swerdlow, A. J. (2012). Endometrial cancer survival after breast cancer in relation to tamoxifen treatment:
Pooled results from three countries. Breast cancer research, 14(3), [91]. https://doi.org/10.1186/bcr3206
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
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Endometrial cancer survival after breast cancer in
relation to tamoxifen treatment: Pooled results
from three countries
Michael E Jones1*, Flora E van Leeuwen2, Wilhelmina E Hoogendoorn2, Marian JE Mourits3, Harry Hollema4,
Hester van Boven5, Michael F Press6, Leslie Bernstein7 and Anthony J Swerdlow1
Abstract
Introduction: Tamoxifen is an effective treatment for breast cancer but an undesirable side-effect is an increased risk of
endometrial cancer, particularly rare tumor types associated with poor prognosis. We investigated whether tamoxifen
therapy increases mortality among breast cancer patients subsequently diagnosed with endometrial cancer.
Methods: We pooled case-patient data from the three largest case-control studies of tamoxifen in relation to
endometrial cancer after breast cancer (1,875 patients: Netherlands, 765; United Kingdom, 786; United States, 324)
and collected follow-up information on vital status. Breast cancers were diagnosed in 1972 to 2005 with
endometrial cancers diagnosed in 1978 to 2006. We used Cox proportional hazards survival analysis to estimate
hazard ratios (HRs) and 95% confidence intervals (CI).
Results: A total of 1,104 deaths occurred during, on average, 5.8 years following endometrial cancer (32%
attributed to breast cancer, 25% to endometrial cancer). Mortality from endometrial cancer increased significantly
with unfavorable non-endometrioid morphologies (P < 0.0001), International Federation of Gynaecology and
Obstetrics staging system for gynecological malignancy (FIGO) stage (P < 0.0001) and age (P < 0.0001). No overall
association was observed between tamoxifen treatment and endometrial cancer mortality (HR = 1.17 (95% CI: (0.89
to 1.55)). Tamoxifen use for at least five years was associated with increased endometrial cancer mortality (HR =
1.59 (1.13 to 2.25)). This association appeared to be due primarily to the excess of unfavorable histologies and
advanced stage in women using tamoxifen for five or more years since the association with mortality was no
longer significant after adjustment for morphological type and FIGO stage (HR = 1.37 (0.97 to 1.93)). Those patients
with endometrioid tumors, who stopped tamoxifen use at least five years before their endometrial cancer
diagnosis, had a greater mortality risk from endometrial cancer than endometrioid patients with no tamoxifen
exposure (HR = 2.11 (1.13 to 3.94)). The explanation for this latter observation is not apparent.
Conclusions: Patients with endometrial cancer after breast cancer who received tamoxifen treatment for five years
for breast cancer have greater endometrial cancer mortality risk than those who did not receive tamoxifen. This can
be attributed to non-endometrioid histological subtypes with poorer prognosis among long term tamoxifen users.
Introduction
Tamoxifen is an effective treatment for breast cancer
[1,2] but an undesirable side-effect is the increased risk
of endometrial cancer in postmenopausal women [3-8],
particularly rare tumor types [5,6,8,9] associated with
poor prognosis [10]. Although the number of cases of
endometrial cancer occurring after tamoxifen is modest
(for example, 0.3% taking tamoxifen for approximately
five years versus 0.1% not taking it [2]), there is concern
that tamoxifen-induced endometrial cancers may have
poorer survival [6,11], even after allowance for histo-
pathologic characteristics [12]. The side-effects of
tamoxifen are unlikely to outweigh the benefits in breast
cancer patients [13], but any detrimental effects on
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survival would have implications for endometrial cancer
surveillance following treatment [14], and would be
important in decisions about the prophylactic use of
tamoxifen by women without breast cancer [15]. To
address these issues we have pooled patients from the
three largest case-control studies of endometrial cancer
after breast cancer [3-6] to examine mortality from
endometrial cancer in relation to tamoxifen treatment.
Materials and methods
The case series from three case-control studies of endo-
metrial cancer after breast cancer were pooled. These
studies from the Netherlands (NL) (nine regional cancer
registries contributing to the Netherlands Cancer Regis-
try), the United Kingdom (UK) (regional cancer regis-
tries in England, Scotland and Wales), and the United
States (US) (Surveillance, Epidemiology and End Results
(SEER) registries in four regions: Atlanta, Iowa, Los
Angeles County, and Seattle-Puget Sound) have each
been described previously [3-6]. Each study received
appropriate ethical approval(s). The majority of data
were abstracted from medical case-notes without patient
contact; however, informed consent was obtained in the
US where patients were interviewed. Briefly, each case-
control study was population-based and included
patients diagnosed with endometrial cancer after breast
cancer during defined periods (NL (n = 765): 1978 to
1997; UK (n = 786): 1988 to 1996; US (n = 324): 1978
to 1993). The endometrial cancer diagnosis had to have
occurred at least three months after the breast cancer
diagnosis (six months for the US study). Patients were
excluded if they had had a cancer (other than non-mela-
noma skin cancer or in situ cervical cancer) diagnosed
before their breast cancer or between the diagnosis of
the initial primary breast cancer and the subsequent
endometrial cancer (except non-melanoma skin cancer,
in situ cervical cancer or breast cancer). Information on
tamoxifen treatment was abstracted from medical
records and in Los Angeles, confirmed in interviews. At
follow-up for survival, one patient from the original UK
case-series was no longer eligible (because of erroneous
cancer registry tumor record linkage) and was removed
from this study.
The cases of endometrial cancer from the original
Dutch study were supplemented with patients diagnosed
from 1989 to 2003 (the TAMARISK (Tamoxifen Asso-
ciated Malignancies: Aspects of Risk) retrospective
cohort) [12] from the same nine regional cancer regis-
tries as in the original (ALERT (Assessment of Liver
and Endometrial cancer Risk following Tamoxifen))
study [3,6], except diagnosis of endometrial cancer was
at least 12 months after breast cancer (rather than three
months). In addition, a further 179 Dutch patients diag-
nosed from 2003 to 2006 were included, with
endometrial cancer at least three months after breast




Vital status, date of most recent follow-up, or date of
death and cause, were obtained from medical records,
general practitioners or clinicians, and municipal popu-
lation registries. Follow-up for the ALERT patients was
initially to 1997, with additional follow-up to 2004 for
those patients who had less than four years initial fol-
low-up. Follow-up was to 2003 to 2005 for the
TAMARISK retrospective cohort and to 2004 to 2007
for the TAMARISK prospective cohort. All deaths were
linked through ‘Statistics Netherlands’ [17] to obtain
registered underlying cause of death (which was used in
analyses when cause of death was unknown based on
review of medical records [12]). Within the study period
there were no known emigrations from the Netherlands
in these cohorts.
UK
Vital status and cause of death were ascertained from
hospital case-notes when the initial study data were col-
lected (1996 to 1999). In 2005 further follow-up for vital
status and causes of death was obtained from each of
the regional cancer registries in Britain, and subse-
quently in 2008 further follow-up was obtained by link-
age to the National Health Service Central Register
(NHSCR – a list of virtually every member of the popu-
lation, which routinely receives notifications of events
such as emigrations, cancers, and deaths) [18], and for
those who had died copies of death certificates were
obtained. Vital status could not be determined for ele-
ven (1.4%) patients so for these follow-up was taken to
the date of the last clinical contact as extracted from
case-notes. Thirty-eight cases had deaths recorded as
occurring at the date of diagnosis of endometrial cancer
and were removed from the main analysis.
USA
Data were originally collected on vital status, date of
most recent follow-up or date of death, and cause of
death (based on information from death certificates) for
all patients up to 2000. Additional follow-up was
obtained to the end of 2006 for the Los Angeles County
patients (n = 228), and those not known to be deceased
were additionally checked against the Social Security
Administration’s Death Master File [19] to ascertain any
deaths outside the state of California.
Statistical Analysis
Descriptive analyses by morphological type of endome-
trial cancer were conducted using one way analysis of
variance for continuous variables or Pearson chi-square
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for categorical variables [20]. When comparing indivi-
dual differences between morphological groups, we
adjusted for age at diagnosis of endometrial cancer and
study, using linear regression in the case of continuous
variables and a ‘modified’ Poisson approach with robust
standard errors [21] for binary variables. To assess the
association between tamoxifen treatment and the risk of
death, we calculated hazard ratios using Cox propor-
tional hazards regression [22] with time since diagnosis
of endometrial cancer (follow-up time) as the implicit
regression time scale and stratification by (adjustment
for) attained age (which also is an adjustment for age at
endometrial cancer diagnosis since: age at endometrial
cancer diagnosis = attained age - survival time since
diagnosis), calendar period and, as appropriate, mor-
phology and FIGO stage. Tests for trend were calculated
using continuous data. Women with deaths due to
causes other than the cause under study in cause-speci-
fic analyses were treated as censored on their dates of
death. Where it was not possible to distinguish between
breast and endometrial cancer as cause of death the
patients (n = 37) were not allocated to either cause of
death in the main analyses, but were allocated to each
cause in sensitivity analyses. Patients diagnosed with
endometrial cancer at death (n = 38) were excluded
from the main analysis and tables but were included,
with a survival time of one day and one year, in sensitiv-
ity analyses. For breast cancer and all cause mortality,
we additionally adjusted for age at diagnosis of breast
cancer and extent of breast disease (instead of FIGO
stage). All analyses were carried out using Stata/IC ver-
sion 10.1 [23] and all statistical tests were two-sided.
Results
Descriptive characteristics of the three studies
There were 1,875 patients in the combined study, com-
prising 765 (41%) from the Netherlands, 786 (42%) from
the UK, and 324 (17%) from the US (Table 1). The
median age at diagnosis of breast cancer was 63 years in
the Netherlands, 62 years in the UK study, and 65.5
years in the US study, and the median age at diagnosis
of endometrial cancer was 69 years in each study. The
calendar periods for diagnosis of breast cancer and
endometrial cancer, and the intervals between the two
cancers, reflect the original individual study designs (as
described above). The median interval between cancers
was 5.1 years in the Netherlands study, 6.0 years in the
UK, and 3.0 years in the US. Tamoxifen use was more
commonly recorded for patients in the UK (82%) than
the Netherlands (46%) or US (45%).
Endometrial cancer morphology
In the combined series 60.7% of the endometrial cancers
developed among tamoxifen users. The majority (84%) of
the endometrial cancers were endometrioid adenocarcino-
mas (Table 2), and (after adjustment for study) these were
diagnosed at significantly younger ages than were serous
or clear cell endometrial cancer (P < 0.0001), and carcino-
sarcomas (P = 0.002). FIGO stage was available for 97% of
the cases in the Netherlands, 78% in the US, but only 37%
in the UK study. Where FIGO stage was known, 79% of
tumors were stage I, 10% were stage II and 11% were stage
III or higher, with no significant difference in this distribu-
tion between studies (P = 0.46). Endometrioid tumors
were more likely to be diagnosed at FIGO stage I than
were non-endometrioid tumors (P < 0.001). A significantly
higher proportion of patients with carcinosarcoma had a
history of tamoxifen use than did patients with endome-
trioid carcinoma (P < 0.001). Among tamoxifen users the
patients who developed carcinosarcoma had been treated
with tamoxifen on average 0.9 years longer than the
patients with endometrioid type tumors (P = 0.012).
Patients with carcinosarcomas, or serous or clear cell
endometrial cancers, were more likely to have ceased
tamoxifen use one or more years before diagnosis of endo-
metrial cancer than patients with endometrioid tumors. (P
= 0.010 and P = 0.020 respectively). The average interval
between breast and endometrial tumors was longer for the
unfavorable cancers, such as carcinosarcomas, serous and
clear cell endometrial cancers but the differences were not
statistically significant (P = 0.25).
Follow-up
The 1,875 patients who had both breast and endometrial
cancer were followed on average for 5.8 years (median
4.0 years) with 1,104 deaths (Table 3). For these patients
with breast cancer who had also developed endometrial
cancer 25% to 28% of the deaths were due to endome-
trial cancer, 32% to 35% to breast cancer (type of cancer
death could not be distinguished between the two
causes in 3% of cases), and 40% to all other causes
(including 1.7% to cancer of unknown primary site and
0.5% with cause of death unknown). The five-year survi-
val was 55.5% but this varied from 73% for patients
diagnosed with localized breast cancer and FIGO grade
I endometrial cancer to 16% for patients diagnosed with
metastatic breast cancer or FIGO grade III/IV endome-
trial cancer. For those patients diagnosed with endome-
trial cancer before age 65, five-year survival was 82% for
patients diagnosed with localized breast cancer and
FIGO grade I endometrial cancer and 32% for patients
diagnosed with metastatic breast cancer or FIGO grade
III/IV endometrial cancer.
Mortality
Age at diagnosis of endometrial cancer
Older age at endometrial cancer diagnosis was asso-
ciated with greater risk of dying of endometrial cancer
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Table 1 Characteristics of patients with endometrial cancer after breast cancer, by study
Study Total
NL UK US
N % N % n % N %
Age at diagnosis of breast cancer (years)
< 45 40 5.2 36 4.6 6 1.9 82 4.4
45 to 54 147 19.2 170 21.6 35 10.8 352 18.8
55 to 64 231 30.2 256 32.6 108 33.3 595 31.7
65 to 74 246 32.2 224 28.5 119 36.7 589 31.4
75 to 84 91 11.9 92 11.7 47 14.5 230 12.3
85 and over 10 1.3 8 1.0 9 2.8 27 1.4
Age at diagnosis of endometrial cancer (years)
< 55 72 9.4 94 12.0 24 7.4 190 10.1
55 to 64 183 23.9 215 27.4 71 21.9 469 25.0
65 to 74 277 36.2 238 30.3 138 42.6 653 34.8
75 to 84 184 24.1 187 23.8 74 22.8 445 23.7
85 and over 49 6.4 52 6.6 17 5.2 118 6.3
Year of diagnosis of breast cancer
1972 to 1979 37 4.8 60 7.6 33 10.2 130 6.9
1980 to 1984 98 12.8 196 24.9 122 37.7 416 22.2
1985 to 1989 163 21.3 376 47.8 147 45.4 686 36.6
1990 to 1995 238 31.1 150 19.1 22 6.8 410 21.9
1995 to 1999 152 19.9 4 0.5 0 0.0 156 8.3
2000 to 2005 77 10.1 0 0.0 0 0.0 77 4.1
Year of diagnosis of endometrial cancer
1978 to 1984 16 2.1 0 0.0 38 11.7 54 2.9
1985 to 1989 63 8.2 112 14.3 143 44.1 318 17.0
1990 to 1994 141 18.4 501 63.7 143 44.1 785 41.9
1995 to 1999 257 33.6 173 22.0 0 0.0 430 22.9
2000 to 2006 288 37.6 0 0.0 0 0.0 288 15.4
Extent of disease (breast cancer)a
Localized 362 47.3 317 40.3 198 61.1 877 46.8
Regional extension 295 38.6 150 19.1 121 37.4 566 30.2
Metastatic disease 15 2.0 4 0.5 5 1.5 24 1.3
Unknown 93 12.2 315 40.1 0 0.0 408 21.8
Interval between breast and endometrial cancers (years)
< 1 35 4.6 47 6.0 34 10.5 116 6.2
1 to < 3 192 25.1 135 17.2 126 38.9 453 24.2
3 to < 5 150 19.6 134 17.1 73 22.5 357 19.0
5 to < 10 231 30.2 326 41.5 78 24.1 635 33.9
10 to 29 157 20.5 144 18.3 13 4.0 314 16.8
Morphological type of endometrial cancer
Endometrioid adenocarcinomab 636 83.1 666 84.7 278 85.8 1580 84.3
Serous or clear cellc 64 8.4 24 3.1 20 6.2 108 5.8
Carcinosarcomad 37 4.8 56 7.1 15 4.6 108 5.8
Sarcomae 26 3.4 19 2.4 9 2.8 54 2.9
Not known 2 0.3 21 2.7 2 0.6 25 1.3
All patients 765 100.0 786 100.0 324 100.0 1875 100.0
aLocalized: no lymph node involvement; Regional extension: spread to lymph nodes; bEndometrial adenocarcinoma, mixed cell adenocarcinoma, papillary
endometrial adenocarcinoma; cSerous adenocarcinoma, clear cell adenocarcinoma; dCarcinosarcoma, Mullerian mesodermal mixed tumors; eSarcoma, endometrial
stromal adenocarcinoma, leiomyosarcoma.
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Table 2 Age at diagnosis, tamoxifen use, FIGO stage, and interval between tumors, by morphology of endometrial
cancer after breast cancer
Endometrial cancer morphologya
Endometrioid carcinomab Serous or clear cellc Carcinosarcomad Sarcomae
N = 1,580 N = 108 N = 108 N = 54
Age at diagnosis of endometrial cancer (years)
< 55 165 10.4 4 3.7 8 7.4 12 22.2
55 to 64 413 26.1 19 17.6 17 15.7 15 27.8
65 to 74 553 35.0 39 36.1 39 36.1 17 31.5
75 to 84 363 23.0 34 31.5 33 30.6 9 16.7
85 and over 86 5.4 12 11.1 11 10.2 1 1.9
Mean (SD), years 68.9 (10.3) 73.4 (9.4) 71.2 (10.4) 67.6 (9.5)
analysis of variance (3 d.f.): P < 0.001f
Tamoxifen use
Not used 651 41.2 44 40.7 19 17.6 17 31.5
Used 929 58.8 64 59.3 89 82.4 37 68.5
Pearson chi-sq (3 d.f.): P < 0.0001g
Duration of tamoxifen use among users
Used, < 2 years 272 29.3 19 29.7 11 12.4 10 27.0
2 to < 5 years 326 35.1 19 29.7 31 34.8 12 32.4
5 or more years 285 30.7 23 35.9 37 41.6 13 35.1
Used, duration unknown 46 5.0 3 4.7 10 11.2 2 5.4
Mean (SD), years 4.1 (3.2) 4.1 (2.8) 5.2 (3.3) 4.0 (2.8)
analysis of variance (3 d.f.): P = 0.025g
Tamoxifen, time since last use among users
Still on/≤ 3 months 649 69.9 34 53.1 50 56.2 24 64.9
3 months to < 1 year 70 7.5 5 7.8 5 5.6 3 8.1
1 year to < 3 years 73 7.9 8 12.5 10 11.2 6 16.2
3 years to < 5 years 35 3.8 6 9.4 7 7.9 2 5.4
5 or more years 56 6.0 8 12.5 8 9.0 0 0.0
Used, time unknown 46 5.0 3 4.7 9 10.1 2 5.1
Mean (SD), years 0.8 (2.0) 1.7 (2.8) 1.3 (2.2) 0.7 (1.3)
analysis of variance (3 d.f.): P = 0.002g
FIGO stage
I 914 57.9 46 42.6 35 32.4 21 38.9
II 111 7.0 14 13.0 3 2.8 4 7.4
III/IV 82 5.2 27 25.0 20 18.5 11 20.4
Unknown 473 29.9 21 19.4 50 46.3 18 33.3
Peasron chi-sq (9 d.f.): P < 0.001g
Interval between breast and endometrial cancer (years)
3 to 12 months 102 6.5 8 7.4 3 2.8 2 3.7
1 to < 3 years 400 25.3 17 15.7 16 14.8 15 27.8
3 to < 5 years 305 19.3 18 16.7 18 16.7 12 22.2
5 to < 10 years 508 32.2 47 43.5 46 45.4 21 38.9
10 to 29 years 265 16.8 18 16.7 22 20.4 4 7.4
Mean (SD), years 5.9 (4.3) 6.5 (4.1) 6.9 (3.9) 5.2 (3.2)
analysis of variance (3 d.f.): (P = 0.039)g
Total 1,580 100.0 108 100.0 108 100.0 54 100.0
aExcludes 25 patients where morphology was unknown; bEndometrial adenocarcinoma, mixed cell adenocarcinoma, papillary endometrial adenocarcinoma;
cSerous adenocarcinoma, clear cell adenocarcinoma; dCarcinosarcoma, Mullerian mesodermal mixed tumors; eSarcoma, endometrial stromal adenocarcinoma,
leiomyosarcoma; fadjusted for study; gadjusted for age at diagnosis and study. N, number; SD, standard deviation.
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(trend P < 0.0001, with no evidence for heterogeneity
between studies (P = 0.52)) (Table 4). Subsequent ana-
lyses adjust endometrial mortality for attained age and
time since diagnosis of endometrial cancer, and thus
implicitly also adjust for age at diagnosis.
FIGO stage
Higher FIGO stage was associated with greater endome-
trial cancer death rates (FIGO III/IV versus I: Hazard
Ratio, HR = 13.1; 95% confidence Interval (9.25 to 18.6);
trend P < 0.0001 with no strong evidence for interaction
between studies P = 0.067).
Endometrial cancer morphology
Endometrial cancer mortality was greater for patients
with non-endometrioid endometrial cancer than patients
with endometrioid types across all three studies com-
bined (HR = 5.09; (3.96 to 6.53), P < 0.0001) and within
each study (data not shown), with no evidence for het-
erogeneity between the three studies (P = 0.33); the
greatest increases were seen for carcinosarcomas (HR =
6.66 (4.87 to 9.12)) and sarcomas (HR = 5.65 (3.53 to
9.05)). The HRs were smaller but still significant after
adjustment for FIGO stage (Table 4).
Validity of cause-specific mortality
Extent of disease of breast cancer was unrelated to
endometrial cancer mortality (P = 0.14) but was strongly
related to breast cancer mortality (P < 0.0001). Age at
diagnosis of endometrial cancer (P = 0.23), FIGO stage
(P = 0.34) and endometrial morphology (P = 0.16) were
not related to breast cancer mortality. Conversely, age at
diagnosis of breast cancer was unrelated to endometrial
cancer mortality (P = 0.11). There was no significant
heterogeneity between studies.
Endometrial cancer mortality: tamoxifen use and
morphology
No overall association was observed between tamoxifen
treatment and endometrial cancer mortality (HR = 1.17
(95% CI: (0.89 to 1.55)); however, tamoxifen use for at
least five years was associated with increased endome-
trial cancer mortality (HR = 1.59 (1.13 to 2.25)). After
adjustment for morphological type and FIGO stage, five
years tamoxifen use was no longer significantly asso-
ciated with endometrial cancer mortality (HR = 1.37
(0.97 to 1.93)) overall or when stratified by morphology
(Table 5). When analyzed by cumulative dose of tamoxi-
fen, patients with cumulative doses over 30,000 mg (for
example, 20 mg per day for 4.1 years) had modestly ele-
vated endometrial cancer mortality. There was no asso-
ciation with daily tamoxifen dose.
Endometrial cancer mortality risk among women who
stopped tamoxifen use at least five years before their
Table 3 Follow-up, vital status and cause of death for patients with endometrial cancer after breast cancer, by study
Study Combined
NL UK US
Number of subjects 765 786 324 1875
Total follow-up time (person-years) 2,676.6 5,552.2 2,731.5 10,960.3
Maximum follow-up (years) 16.6 20.3 25.5 25.5
Median length of follow-up (years) 2.6 5.2 8.1 4.0
Vital status at end of follow-up (n, %)
Alive 470 61.4% 202 26% 99 31% 771 41.1%
Deceased 295 38.6% 584 74% 225 69% 1,104 58.9%
Cause of death (n, %)
Breast cancer 92 31% 198 34% 63 28% 353 32.0%
Endometrial cancer 85 29% 151 26% 41 18% 277 25.1%
Breast or cancera 28 9% 9 2% 0 0% 37 3.4%
All other causesb, c 90 31% 226 39% 121 54% 437 39.6%
All causes 295 100% 584 100% 225 100% 1,104 100.0%


































aNot possible to differentiate between breast and endometrial cancer as cause of death; b15 (2.6%) patients in UK and 4 (1.8%) in the USA study had cancer as
cause of death, but primary site unknown; c4 (1.4%) patients in NL and 2 (0.3%) in UK study had an unknown cause of death; ddeaths due to causes other than
endometrial cancer are censored on date of death. CI, confidence interval; n, number.
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endometrial cancer diagnosis was twice that of women
who had never used tamoxifen and the trend with cessa-
tion among users (HR = 1.11 per year since last use
(1.05 to 1.18)) remained statistically significant after
adjustment for morphological type, duration of tamoxi-
fen use, FIGO stage and interval between breast and
endometrial cancer.
There was a strong trend of increasing mortality with
increasing interval between breast cancer and endome-
trial cancer diagnosis (P = 0.0001), which, after stratifi-
cation by morphology, remained statistically significant
among those with endometrioid tumors (P < 0.0003).
The trend with interval was also stronger in tamoxifen
users than non-users (P = 0.044) and among users
remained statistically significant even after adjustment
for duration of tamoxifen use (P = 0.032). (For breast
cancer mortality, risk of dying decreased as the interval
between tumors increased (P = 0.003), but all-cause
mortality did not vary with interval between tumors (P
= 0.085)).
Time since last tamoxifen use and interval between
diagnoses of breast and endometrial cancer are related
Table 4 Endometrial cancer mortality in relation to age at diagnosis, FIGO stage and morphology of endometrial
cancer
Patients Endometrial cancer mortality
N Deaths HR 95% CI
Age at diagnosis of endometrial cancera
< 55 190 14 1.00 baseline
55 to 64 469 51 1.57 0.87, 2.84
65 to 74 653 87 2.13 1.21, 3.75
75 to 84 445 92 3.65 2.08, 6.43
85 and over 118 33 5.69 3.03, 10.7
Heterogeneity (4 d.f.) P < 0.0001
Trend (1 d.f.) P < 0.0001
FIGO stageb
I 1016 64 1.00 baseline
II 132 26 3.34 2.11, 5.28
III/IV 140 67 13.1 9.25, 18.6
Unknown 587 120 2.92 2.06, 4.14
Heterogeneity (3 d.f.) P < 0.0001
Morphologyc
Endometrioidd 1580 162 1.00 baseline
Serous or clear celle 108 32 2.25 1.51, 3.37
Carcinosarcomaf 108 54 5.41 3.92, 7.45
Sarcomag 54 20 3.93 2.42, 6.38
Unknown 25 9 4.11 2.06, 8.14
Heterogeneity (4 d.f.) P < 0.0001
All non-endometrioidh 270 106 3.75 2.88, 4.87
Morphology by tamoxifen usec
Tamoxifen users:
- non-endometrioid 190 79 3.32 2.06, 5.35
-endometrioid 929 105 1.00 baseline
Tamoxifen non-user
- non-endometrioid 80 27 3.88 2.86, 5.28
-endometrioid 651 57 1.00 baseline
Heterogeneity interactionh (1 d.f.) P = 0.57
Morphology unknown: 25 9
aAdjusted for time since diagnosis of endometrial cancer, study, calendar period, FIGO stage;
badjusted for time since diagnosis of endometrial cancer, study, calendar period, attained age;
cadjusted for time since diagnosis of endometrial cancer, study, calendar period, FIGO stage, attained age;
d endometrial adenocarcinoma, mixed cell adenocarcinoma, papillary endometrial adenocarcinoma;
eserous adenocarcinoma, clear cell adenocarcinoma; fcarcinosarcoma, Mullerian mesodermal mixed tumors; gsarcoma, endometrial stromal adenocarcinoma,
leiomyosarcoma; hExcludes those where morphology was unknown. CI, confidence interval; FIGO, International Federation of Gynaecology and Obstetrics; HR,
hazard ratio; N, number.
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Table 5 Endometrial cancer mortality and tamoxifen use, by morphology
All morphological types Morphologya
Endometrioid Non-endometrioidb
d n HRc 95% CI d n HRd 95% CI d n HRd 95% CI
Tamoxifen use
Not used 86 737 1.00 baseline 57 651 1.00 baseline 27 80 1.00 baseline
Used 191 1138 1.17 0.89, 1.55 105 929 1.01 0.72, 1.43 79 190 1.19 0.74, 1.89
P-het (1 d.f.) = 0.26 P-interaction (1 d.f.) = 0.57
Duration of tamoxifen use
Not used 86 737 1.00 baseline 57 651 1.00 baseline 27 80 1.00 baseline
Used, < 2 years 29 313 0.71 0.46, 1.09 20 272 0.77 0.46, 1.29 8 40 0.50 0.23, 1.12
2 - < 5 years 61 397 1.18 0.84, 1.67 27 326 0.82 0.51, 1.32 30 62 1.64 0.94, 2.86
5 or more years 86 365 1.59 1.13, 2.25 49 285 1.43 0.94, 2.19 35 73 1.56 0.91, 2.69
Used, duration unknown 15 63 2.45 1.38, 4.36 9 46 3.14 1.50, 6.57 6 15 1.29 0.51, 3.26
P-het (4 d.f.) = 0.0002 P-trend interaction (1 d.f.) = 0.36
P-trend (1 d.f.) = 0.0055 P-trend (1 d.f.) = 0.0023 P-trend (1 d.f.) = 0.22
Cumulative tamoxifen dose (mg)e
Not used 86 737 1.00 baseline 57 651 1.00 baseline 27 80 1.00 baseline
Used, < 7500 16 132 0.90 0.52, 1.55 12 114 1.06 0.57, 2.00 4 18 0.57 0.20, 1.65
7500 to < 15,000 15 159 0.72 0.41, 1.26 9 138 0.63 0.31, 1.29 5 20 0.83 0.31, 2.18
15,000 to < 30,000 32 239 1.06 0.70, 1.61 15 199 0.84 0.47, 1.51 15 35 1.38 0.72, 2.64
30,000 to < 60,000 56 294 1.40 0.97, 2.02 23 230 0.91 0.55, 1.51 31 59 1.64 0.94, 2.87
≥ 60,000 52 230 1.40 0.95, 2.05 32 185 1.29 0.81, 2.07 18 41 1.26 0.68, 2.36
Used, amount unknown 20 84 2.13 1.26, 3.58 14 63 2.86 1.54, 5.33 6 17 1.11 0.44, 2.81
P-het (6 d.f.) = 0.022 P-trend interaction (1 d.f.) = 0.89
P-trend (1 d.f.) = 0.10 P-trend (1 d.f.) = 0.38 P-trend (1 d.f.) = 0.36
Daily tamoxifen dose (mg/day)
Not used 86 737 1.00 baseline 57 651 1.00 baseline 27 80 1.00 baseline
< 25 mg/dayf 115 738 1.10 0.81, 1.50 63 610 0.97 0.66, 1.43 49 119 1.32 0.79, 2.20
≥ 25 mg/dayg 62 343 1.25 0.88, 1.76 31 277 0.94 0.59, 1.48 27 59 1.11 0.64, 1.93
Used, dose unknown 14 57 1.74 0.96, 3.15 11 42 2.65 1.35, 5.20 3 12 0.72 0.21, 2.50
P-het (3 d.f.) = 0.28 P-trend interaction (1 d.f.) = 0.90
P-trend (1 d.f.) = 0.86 P-trend (1 d.f.) = 0.68 P-trend (1 d.f.) = 0.60
Time since last use (based on date of diagnosis of endometrial cancer)
Not used 86 737 1.00 baseline 57 651 1.00 baseline 27 80 1.00 baseline
Still on/≤ 3 months 107 764 0.92 0.68, 1.26 62 649 0.82 0.56, 1.21 42 108 1.11 0.66, 1.88
3 months to < 1 year 14 87 1.12 0.63, 1.99 9 70 1.27 0.62, 2.62 4 13 0.64 0.22, 1.85
1 year to < 3 years 20 100 1.62 0.99, 2.67 7 73 0.90 0.41, 1.98 12 24 1.64 0.82, 3.30
3 years to < 5 years 13 53 1.91 1.05, 3.46 5 35 1.39 0.55, 3.50 6 15 1.82 0.73, 4.55
5 or more years 22 72 2.22 1.36, 3.61 13 56 2.11 1.13, 3.94 9 16 1.52 0.68, 3.38
Used, time unknown 15 62 2.11 1.19, 3.72 9 46 3.08 1.49, 6.38 6 14 1.23 0.49, 3.11
P-het (6 d.f.) = 0.0007 P-trend interaction (1 d.f.) = 0.52
P-trend (1 d.f.) = 0.012 P-trend (1 d.f.) = 0.0033 P-trend (1 d.f.) = 0.20
Interval between tumors
3 - 11 months 9 116 0.83 0.40, 1.69 8 102 1.08 0.49, 2.38 1 13 0.19 0.02, 1.43
1 - 2 years 44 453 1.00 baseline 29 400 1.00 baseline 14 48 1.00 baseline
3 - 4 years 47 357 1.33 0.88, 2.01 22 305 1.02 0.59, 1.79 22 48 1.16 0.58, 2.33
5 - 9 years 110 635 1.62 1.13, 2.32 56 508 1.41 0.89, 2.23 52 117 1.31 0.71, 2.42
10 - 29 years 67 314 2.06 1.38, 3.08 47 265 2.18 1.35, 3.53 17 44 1.01 0.47, 2.16
P-het (4 d.f.) = 0.0017 P-interaction (1 d.f.) = 0.13
P-trend (1 d.f.) = 0.0048 P-trend (1 d.f.) = 0.0003 P-trend (1 d.f.) = 0.49
aExcludes those (9 endometrial deaths among 25 patients) where morphology was missing; bSerous and clear cell, carcinosarcoma, sarcoma, excludes those
where morphology unknown; cAdjusted for time since diagnosis of endometrial cancer, study, calendar period, and attained age; dAdjusted for time since
diagnosis of endometrial cancer, study, calendar period, attained age, and FIGO stage; eTrend evaluated on log10 transformed cumulative dose;
fMostly 20 mg/day; gMostly 40 mg/day. CI, confidence interval; d, number of deaths attributed to endometrial cancer; HR, hazard ratio; n, number of patients.
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(that is, only those with an interval between tumors of
five or more years could have ceased tamoxifen use five
or more years ago) but even among those patients with
an interval of five or more years (that is, those with the
potential for five or more years cessation) mortality was
still elevated among those with five or more years since
cessation of tamoxifen (HR = 2.06 (1.18 to 3.60)). When
considering calendar period of diagnosis, since the indi-
cations for treatment and cessation of tamoxifen may
have changed over time, there was no significant differ-
ence in trend with cessation among tamoxifen users for
those diagnosed with breast cancer before 1990 (com-
pared with those diagnosed in 1990 or later, P = 0.84)
or with endometrial cancer before 1995 (compared with
those diagnosed in 1995 or later, P = 0.53).
Discussion
We accrued 1,875 patients, with 1,104 deaths of which
227 were due to endometrial cancer, by pooling the
three largest case-control studies of endometrial cancer
after breast cancer [3-6]. The number of cases of endo-
metrial cancer occurring in breast cancer trial settings
at present is modest (for example, 182 cases of uterine
cancer reported in the Early Breast Cancer Trialists’
Collaborative Group (EBCTCG) meta-analysis of 20
trials [2], and 102 cases in the National Surgical Adju-
vant Breast and Bowel Project (NSABP) trial comparing
prophylactic tamoxifen with raloxifene [24]), so although
our data are observational we have a large number of
cases, some of rarer histologies, with which to examine
endometrial cancer survival after tamoxifen use. A pre-
vious report using a subset of the pooled data [12]
showed increased endometrial cancer mortality with
tamoxifen use, but did not have as many patients or as
much follow-up time as we have in the pooled data.
We found that women with five or more years of
tamoxifen use had 59% greater risk of endometrial can-
cer death than non-users, which was mostly attributable
to the occurrence of endometrial cancer morphologies
among tamoxifen users with less favorable prognosis,
for example, carcinosarcomas. Several earlier studies
have shown that tamoxifen greatly increases the risk of
developing non-endometrioid tumors [5,6,8,9] and in
the data reported here endometrial cancer mortality
attributed to these morphological types was 2.3 to 5.4
times that of endometrioid types. Beyond the conse-
quence of tamoxifen increasing the incidence of these
tumors with poor prognosis [10], we saw no further
adverse effect of tamoxifen dose or cumulative dose on
endometrial cancer survival. In line with our results,
genomic analyses suggest there are no differences
between tamoxifen-induced tumors, either endometrioid
or non-endometrioid, and those tumors occurring in
patients without tamoxifen use [16,25,26]. Our data
show, however, that patients with endometrioid tumors
who had stopped tamoxifen five or more years before
diagnosis of endometrial cancer had greater endometrial
cancer-specific mortality risk. (The statistical power to
examine this among patients with non-endometrioid
tumors was low because these tumor types were less
common.)
Although some of the women in this study may have
received tamoxifen when distant metastases arose, and
their prognosis would have been poor in relation to
breast cancer survival, this does not preclude them from
contributing survival time for analyses of tamoxifen use
and endometrial cancer mortality (just as women who
had other serious diseases are able to contribute to the
analyses). As a demonstration of the validity of the
cause-specific survival analyses, we found that extent of
the breast disease was strongly predictive of breast can-
cer mortality but it was not associated with endometrial
cancer mortality. Conversely, age at diagnosis of endo-
metrial cancer, FIGO stage and morphology were
strongly predictive of endometrial cancer mortality but
not breast cancer mortality. We, therefore, believe our
analyses are valid, whether tamoxifen was used for
metastatic disease or in an adjuvant setting.
Mortality risk was elevated in the patients for whom
tamoxifen use was known but the details of the dose or
duration was missing. However, it is probable that this
is an artefact related to the greater chance of destruction
or loss of some part of the medical case-note history
among patients who had died by the time of data collec-
tion. Our conclusions were not materially affected by
the missing data because few were missing, for example,
< 3% were missing the duration of tamoxifen use.
The cases from the three study populations were all
ascertained from regional population-based cancer regis-
tries [3-6,12], although some patients were not available
for the analyses. For the UK, 208 provisionally eligible
patients were identified but their case notes could not
be located or had insufficient information for the origi-
nal case-control study (and subsequent follow-up for
mortality). In the US, five patients were excluded from
the case-control study. None were excluded in the NL,
yet there was no evidence of heterogeneity between the
studies, suggesting there was little, if any, bias due to
case under-ascertainment. Furthermore, the one- and
five- year survival rates seen here for endometrial cancer
within each study were similar to published NL, UK and
US rates [27,28], which suggests under-ascertainment
did not materially affect the results.
Follow-up for mortality was comprehensive because
population-based cancer registries covered each region,
and additional information was available from medical
records, general practitioners, clinicians, and national
death registers. It is therefore unlikely that any
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significant migration outside of the study regions
occurred, or that any unascertained deaths occurred.
Thirty-eight patients diagnosed with endometrial cancer
at death were excluded from the analysis because they
contributed no survival follow-up, and their inclusion in
sensitivity analyses made no material difference to the
results. It was not possible to distinguish between breast
and endometrial cancer as cause of death in 37 cases
and these patients were censored at date of death in the
main analyses, and their inclusion as endometrial cancer
deaths strengthened the association with cumulative
dose but made little material change to the other results.
An issue in the interpretation of the results is the
attribution of cause of death to a single underlying
cause in the presence of co-morbidity. We saw opposing
trends in breast and endometrial cancer mortality with
interval between tumors, and although longer follow-up
since breast cancer would be expected to be associated
with lower breast cancer death rates it is possible that
deaths occurring after a long interval between tumors
may have been more likely to be assigned to the most
recently diagnosed tumor (that is, endometrial cancer).
To make some allowance for this we adjusted for inter-
val between tumors in the analyses and the main results
remained the same: among patients with endometrioid
tumors there was no association between endometrial
cancer mortality and tamoxifen use, but increased mor-
tality if tamoxifen had stopped at least five years before
diagnosis of endometrial cancer.
Endometrioid endometrial tumors may be more likely
to present with vaginal bleeding and therefore be diag-
nosed earlier than non-endometerioid tumors, and
indeed we saw that these tumor types were more likely
to be of a lower FIGO grade at diagnosis. However,
even among the patients with only endometerioid
tumors we saw increased mortality in those who had
stopped tamoxifen five or more years before endometrial
cancer diagnosis compared with those who had not
received tamoxifen.
One possibility to consider is that gynecologic surveil-
lance could have been less comprehensive after patients
had ceased tamoxifen, resulting in delayed diagnosis and
poorer prognosis. We investigated this hypothesis by
looking at the effect of cessation among patients diag-
nosed with endometrial cancer before and after 1995
(when the first major reports of increased risk of endo-
metrial cancer with tamoxifen use appeared [3,7,13] and
awareness of the issue presumably increased), but we
found that this did not change our findings, nor if we
split the data at 1990 (when the first randomized trial
results appeared linking tamoxifen to second cancers
[29]).
If there is a real effect of time since last use we are
unable to suggest an explanation for the increased risk
but speculate that endometrioid endometrial cancers
developing after long induction times may have different
characteristics from those occurring in closer proximity
to tamoxifen exposure.
Conclusions
Patients with endometrial cancer after five years use of
tamoxifen for breast cancer have increased mortality
from endometrial cancer, due to the occurrence of less
favorable morphological subtypes of endometrial cancer
in long term tamoxifen users. Patients who had stopped
tamoxifen use five or more years before diagnosis of
endometrioid endometrial cancer had increased endo-
metrial cancer mortality, a finding that warrants further
research.
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